Andrew Hollman Meyer
Chief Business Officer · Janux Therapeutics, Inc.
- 2024
- Dec 3, 2025
- 4
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Andrew Hollman Meyer files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Janeen Noel Doyle - $57K in JANX purchases and sales in the last 12 months
- Maria Dobek - $29K in JANX purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Andrew Hollman Meyer?
Andrew Hollman Meyer is a corporate insider, tracked as Chief Business Officer of Janux Therapeutics, Inc. (JANX). InsiderAlpha holds 4 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
When did Andrew Hollman Meyer last file a Form 4?
The most recent primary Form 4 on record is dated 3 December 2025, one of 4 filings going back to 2024.
Has Andrew Hollman Meyer been buying or selling stock?
Recorded transactions: 0 open-market purchases and 4 open-market sales ($711K) across all tracked filings.
